Osteoporosis: denosumab best after bisphosphonate treatment

  • Miller PD & al.
  • Osteoporos Int
  • 28 Nov 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A pooled analysis finds that denosumab is superior in efficacy to bisphosphonates for osteoporotic postmenopausal women who are transitioning off oral bisphosphonates.

Why this matters

  • Findings suggest that women with osteoporosis can safely and effectively transition from a bisphosphonate to denosumab.

Study design

  • Patient-level pooled analysis of 4 randomized controlled trials (RCTs; n=2850) of osteoporotic women transitioning from oral bisphosphonates to either 60-mg denosumab once every 6 months or a bisphosphonate (oral alendronate, risedronate, ibandronate, or intravenous zoledronic acid).
  • Funding: Amgen Inc.

Key results

  • Denosumab (vs bisphosphonates) was associated with greater bone mineral density (BMD), ranging from 0.6% to 2.0%.
    • Lumbar spine: 2% (95% CI, 1.8%-2.3%).
    • Total hip: 1.3% (95% CI, 1.1%-1.5%).
    • Femoral neck: 1.2% (95% CI, 1.0%-1.4%).
    • 1/3 radius: 0.6% (95% CI, 0.3%-1.0%).
  • Denosumab (vs bisphosphonates) was associated with greater decrease in bone turnover markers in the serum, CTX-1 and P1NP, at months 1, 6, and 12 (all Ps<.0001>
  • CTX-1 change at month 1 was correlated with percentage increase in lumbar spine and total hip BMD at month 12 with denosumab (r=−0.16 [P=.0004] and r=−0.22 [P<.0001 respectively but not with bisphosphonate and r="0.08">
  • No differences between groups in adverse events.

Limitations

  • Open-label design of 2 of 4 RCTs.
  • No assessment of fracture risk.